{"filing":{"accession_number":"0001140361-26-037767","cik":"0001005286","ticker":"LFCR","company_name":"LIFECORE BIOMEDICAL, INC. \\DE\\","form":"8-K","filing_date":"2026-09-28","report_date":"2026-09-27","primary_document":"ef20082009_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1005286/000114036126037767/ef20082009_8k.htm"},"events":[{"id":35353,"run_id":32559,"accession_number":"0001140361-26-037767","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"summary":"Lifecore Biomedical entered into a definitive Agreement and Plan of Merger with Webster Equity Partners affiliates on September 27, 2026, whereby the Company will become a wholly owned subsidiary of Parent. Common stockholders will receive $6.28 per share in cash plus contingent value rights, with total consideration up to $663.7 million assuming full CVR achievement, subject to stockholder approval and regulatory clearance with expected closing in Q4 2026.","company_name":"LIFECORE BIOMEDICAL, INC. \\DE\\","ticker":"LFCR","filing_date":"2026-09-28","form":"8-K","submitted_at":null,"items":[{"id":39378,"accession_number":"0001140361-26-037767","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"reasoning":"Lifecore Biomedical entered into a definitive Agreement and Plan of Merger with Webster Equity Partners affiliates on September 27, 2026, whereby Merger Sub will merge with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent. The transaction is valued at up to $663.7 million assuming full CVR achievement, with common stockholders receiving $6.28 per share in cash plus contingent value rights. This is a material acquisition/change of control transaction requiring stockholder approval and regulatory clearance, clearly falling under Item 1.01 (Entry into a Material Definitive Agreement) and the ma_activity event type.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T12:58:02.363368+00:00","company_name":"","ticker":null,"filing_date":""},{"id":39379,"accession_number":"0001140361-26-037767","item_number":"7.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"The filing discloses entry into a definitive merger agreement whereby Webster Equity Partners will acquire Lifecore Biomedical for $6.28 per share in cash plus contingent value rights, with total consideration up to $663.7 million. The press release explicitly states \"Lifecore Biomedical to be Acquired by Webster Equity Partners\" and describes a material acquisition transaction with stockholder approval required and expected closing in Q4 2026. This is a clear material acquisition event under Item 1.01/2.01 framework, disclosed via Item 7.01 Regulation FD.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T12:58:02.363368+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":39378,"accession_number":"0001140361-26-037767","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"reasoning":"Lifecore Biomedical entered into a definitive Agreement and Plan of Merger with Webster Equity Partners affiliates on September 27, 2026, whereby Merger Sub will merge with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent. The transaction is valued at up to $663.7 million assuming full CVR achievement, with common stockholders receiving $6.28 per share in cash plus contingent value rights. This is a material acquisition/change of control transaction requiring stockholder approval and regulatory clearance, clearly falling under Item 1.01 (Entry into a Material Definitive Agreement) and the ma_activity event type.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T12:58:02.363368+00:00","company_name":"LIFECORE BIOMEDICAL, INC. \\DE\\","ticker":"LFCR","filing_date":"2026-09-28"},{"id":39379,"accession_number":"0001140361-26-037767","item_number":"7.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"The filing discloses entry into a definitive merger agreement whereby Webster Equity Partners will acquire Lifecore Biomedical for $6.28 per share in cash plus contingent value rights, with total consideration up to $663.7 million. The press release explicitly states \"Lifecore Biomedical to be Acquired by Webster Equity Partners\" and describes a material acquisition transaction with stockholder approval required and expected closing in Q4 2026. This is a clear material acquisition event under Item 1.01/2.01 framework, disclosed via Item 7.01 Regulation FD.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-28T12:58:02.363368+00:00","company_name":"LIFECORE BIOMEDICAL, INC. \\DE\\","ticker":"LFCR","filing_date":"2026-09-28"}]}